Heron Therapeutics, Inc.
HRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818033
No open-market purchases or sales by Heron Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Holders of 5% or more of HRTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Heron Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 13D/A | 17.50%29.1M shares | – | Aug 12, 20251 filing | Aug 12, 2025 | SEC |
| Clearline Capital LP | 13G | 5.30%9.71M shares | New | Nov 26, 20251 filing | Nov 26, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Heron Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 26, 202510:15 AM ET | Clearline Capital LPand 2 others | 13G | 5.30%9.71M shares | New | Sep 30, 2025 | SEC |
| Oct 30, 20253:16 PM ET | Vanguard Group Inc | 13G/A | 4.61%8.46M shares | –Below 5% | Sep 30, 2025 | SEC |
| Aug 12, 20256:00 PM ET | Rubric Capital Management LPand 1 other | 13D/A | 17.50%29.1M shares | – | Aug 8, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Heron Therapeutics, Inc. shares.
No Form 144 notices for Heron Therapeutics, Inc. are on file.